Want to create an interactive transcript for this episode?
Podcast: PeerView Clinical Pharmacology CME/CNE/CPE Video
Episode: Amit Bar-Or, MD, FRCPC - Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
Description: Go online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials...